As observed in the clinical trial NCT03072043, treatment with eprenetapopt and azacytidine was beneficial to patients with myelodysplastic syndromes and with oligoblastic acute myeloid leukemia, which carries p53 mutants [73]. The gene discussed is TP53; the disease is myelodysplastic syndrome.